Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 4/20 | 0.56 |
| ▸ | DBF4 | Q9UBU7 | 4/20 | 0.56 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460614 | 0.88 | CDC7 (0.57) | CDC7DBF4TRPM8PTPN11MAPT | |
| SCHEMBL8867203 | 0.87 | CDC7 (0.56) | CDC7DBF4TRPM8PTPN11MAPT | |
| SCHEMBL8868127 | 0.85 | CDC7 (0.54) | CDC7DBF4TRPM8PTPN11MAPT | |
| SCHEMBL17309789 | 0.84 | CDC7 (0.53) | CDC7DBF4TRPM8PTPN11MAPT | |
| SCHEMBL8866949 | 0.83 | CDC7 (0.52) | CDC7DBF4TRPM8PTPN11MAPT | |
| SCHEMBL8868119 | 0.83 | CDC7 (0.54) | CDC7DBF4TRPM8PTPN11MAPT | |
| SCHEMBL17309825 | 0.82 | CDC7 (0.50) | CDC7DBF4TRPM8PTPN11MAPT | |
| SCHEMBL8868456 | 0.82 | CDC7 (0.50) | CDC7DBF4TRPM8PTPN11MAPT | |
| SCHEMBL469541 | 0.82 | XDH (0.54) | CDC7DBF4LMNA | |
| SCHEMBL8867675 | 0.82 | CDC7 (0.50) | CDC7DBF4TRPM8PTPN11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952513-B1 | AZOLE BENZENE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-10301300-B2 | Xanthine oxidase inhibitor | TEIJIN LIMITED (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20180244665-A1 | XANTHINE OXIDASE INHIBITOR | TEIJIN PHARMA LIMITED (JP) | 2018-08-30 | — | — | US | disclosed |
| US-20170217948-A1 | XANTHINE OXIDASE INHIBITOR | TEIJIN PHARMA LIMITED (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9388174-B2 | Azole benzene derivative | TEIJIN PHARMA LIMITED (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20150376174-A1 | AZOLE BENZENE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2952513-A1 | AZOLE BENZENE DERIVATIVE | Teijin Pharma Limited (JP) | 2015-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301300-B2 | Xanthine oxidase inhibitor | XDH, PNPO, PCSK9 | CDC7 4454/4885DBF4 3869/4885TRPM8 2847/4885 |
| US-20180244665-A1 | XANTHINE OXIDASE INHIBITOR | XDH, PNPO, PCSK9 | CDC7 4454/4885DBF4 3869/4885TRPM8 2847/4885 |
| US-20150376174-A1 | AZOLE BENZENE DERIVATIVE | XDH, NLRP3, ALPI | CDC7 2473/4885DBF4 946/4885TRPM8 2085/4885 |
| US-20170217948-A1 | XANTHINE OXIDASE INHIBITOR | XDH, PNPO, PCSK9 | CDC7 4454/4885DBF4 3869/4885TRPM8 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.